# CD123/CLL1 CAR-T Cells for R/R AML (STPHI_0001)

> **NCT03631576** · PHASE2,PHASE3 · UNKNOWN · sponsor: **Fujian Medical University** · enrollment: 20 (estimated)

## Conditions studied

- Relapsed/Refractory AML

## Interventions

- **BIOLOGICAL:** CD123/CLL1 CAR-T Cells

## Key facts

- **NCT ID:** NCT03631576
- **Lead sponsor:** Fujian Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-08-10
- **Primary completion:** 2021-08-10
- **Final completion:** 2021-08-10
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2020-01-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03631576

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03631576, "CD123/CLL1 CAR-T Cells for R/R AML (STPHI_0001)". Retrieved via AI Analytics 2026-07-17 from https://api.ai-analytics.org/clinical/NCT03631576. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*